RT Journal Article
SR Electronic
T1 SARS-CoV-2 seropositivity and subsequent infection risk in healthy young adults: a prospective cohort study
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.01.26.21250535
DO 10.1101/2021.01.26.21250535
A1 Letizia, Andrew G.
A1 Ge, Yongchao
A1 Vangeti, Sindhu
A1 Goforth, Carl
A1 Weir, Dawn L
A1 Kuzmina, Natalia A.
A1 Chen, Hua Wei
A1 Ewing, Dan
A1 Soares-Schanoski, Alessandra
A1 George, Mary-Catherine
A1 Graham, William D.
A1 Jones, Franca
A1 Bharaj, Preeti
A1 Lizewski, Rhonda A.
A1 Lizewski, Stephen A.
A1 Marayag, Jan
A1 Marjanovic, Nada
A1 Miller, Clare
A1 Mofsowitz, Sagie
A1 Nair, Venugopalan D.
A1 Nunez, Edgar
A1 Parent, Danielle M.
A1 Porter, Chad K.
A1 Ana, Ernesto Santa
A1 Schilling, Megan
A1 Stadlbauer, Daniel
A1 Sugiharto, Victor
A1 Termini, Michael
A1 Sun, Peifang
A1 Tracy, Russell. P.
A1 Krammer, Florian
A1 Bukreyev, Alexander
A1 Ramos, Irene
A1 Sealfon, Stuart C.
YR 2021
UL http://medrxiv.org/content/early/2021/01/29/2021.01.26.21250535.abstract
AB Background The risk of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) subsequent infection among seropositive young adults was studied prospectively.Methods The study population comprised 3,249 predominantly male, 18-20-year-old Marine recruits. Upon arrival at a Marine-supervised two-week quarantine, participants were assessed for baseline SARS-CoV-2 IgG seropositivity, defined as a 1:150 dilution or greater on receptor binding domain and full-length spike protein enzyme-linked immunosorbent (ELISA) assays. SARS-CoV-2 infection was assessed by PCR at initiation, middle and end of the quarantine. After appropriate exclusions, including participants with a positive PCR during quarantine, we performed three biweekly PCR tests in both seropositive and in seronegative groups once recruits left quarantine and entered basic training and baseline neutralizing antibody titers on all subsequently infected seropositive and selected seropositive uninfected participants.Findings Among 189 seropositive participants, 19 (10.1%) had at least one positive PCR test for SARS-CoV-2 during the six-week follow-up (1.1 cases per person-year). In contrast, 1,079 (48.0%) of the 2,247 seronegative participants tested positive (6.2 cases per person-year). The incidence rate ratio was 0.18 (95% CI 0.11-0.28, p<0.00001). Among seropositive recruits, infection was associated with lower baseline full-length spike protein IgG titers (p<0.0001). Compared with seronegative recruits, seropositive recruits had about 10-fold lower viral loads (ORF1ab gene, p<0.005), and trended towards shorter duration of PCR positivity (p=0.18) and more frequent asymptomatic infections (p=0.13). Among seropositive participants, baseline neutralizing titers were detected in 45 of 54 (83.3%) uninfected and in 6 of 19 (31.6%) infected participants during the 6 weeks of observation (ID50 difference p<.0001).Interpretation Seropositive young adults had about one-fifth the risk of subsequent infection compared with seronegative individuals. Although antibodies induced by initial infection are largely protective, they do not guarantee effective SARS-CoV-2 neutralization activity or immunity against subsequent infection. These findings may be relevant for optimization of mass vaccination strategies.Funding Defense Health Agency and Defense Advanced Research Projects AgencyCompeting Interest StatementDP owned stock in Co-Diagnostics Inc during the conduct of the study. DP held stock in Co-Diagnostics, Inc. DS and FK have filed a patent regarding serological assays and for SARS-CoV-2 and Icahn School of Medicine at Mount Sinai has founded a company to commercialize serological assays they developedFunding StatementThis work received funding from the Defense Health Agency through the Naval Medical Research Center (9700130) and from the Defense Advanced Research Projects Agency (contract number N6600119C4022).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Institutional Review Board approval was obtained from the Naval Medical Research Center (protocol number NMRC.2020.0006) in compliance with all applicable U.S. federal regulations governing the protection of human subjects.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).Yes I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAnonymized data will be made available on request.